Organogenesis (NASDAQ:ORGO) Upgraded by Zacks Investment Research to Hold

Zacks Investment Research upgraded shares of Organogenesis (NASDAQ:ORGO) from a sell rating to a hold rating in a research note published on Wednesday morning, Zacks.com reports.

According to Zacks, “Organogenesis is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. “

Several other research analysts have also recently weighed in on the company. BTIG Research reissued a buy rating and issued a $12.00 price objective on shares of Organogenesis in a research report on Thursday, May 2nd. Credit Suisse Group initiated coverage on Organogenesis in a research report on Thursday, May 2nd. They issued an outperform rating and a $9.00 price objective on the stock. Oppenheimer initiated coverage on Organogenesis in a research note on Wednesday, April 17th. They issued an outperform rating and a $11.00 target price on the stock. CIBC initiated coverage on Organogenesis in a research note on Wednesday, April 17th. They issued an outperform rating and a $11.00 target price on the stock. Finally, SunTrust Banks initiated coverage on Organogenesis in a research note on Thursday, April 11th. They issued a buy rating and a $11.00 target price on the stock. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $10.80.

ORGO stock opened at $7.60 on Wednesday. The stock has a fifty day simple moving average of $7.08. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.87 and a current ratio of 1.07. Organogenesis has a 1-year low of $6.28 and a 1-year high of $310.90.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings data on Friday, May 10th. The company reported ($0.15) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.05). The business had revenue of $57.12 million during the quarter, compared to analyst estimates of $55.12 million. As a group, research analysts predict that Organogenesis will post -0.47 earnings per share for the current year.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.

Recommended Story: Net Income

Get a free copy of the Zacks research report on Organogenesis (ORGO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Organogenesis (NASDAQ:ORGO)

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.